Eternity in Medical Information -- Medisurf
Items 21 ~ 24 of 2176, Page 3 of 272
Abbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing
Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers / Collaboration is a major...
08.14.2019 Abbott
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women ...
08.14.2019 MERCK
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
KEYTRUDA Now Approved for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus in Patients Whose Tumors Express PD-L1 (CP...
07.31.2019 MERCK
Merck Announces Second-Quarter 2019 Financial Results
07.30.2019 MERCK
Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
07.29.2019 MERCK
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)
KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Statistically Significant Improvement in pCR Rates as Neoadjuvant Therapy for TNBC Regardless...
07.29.2019 MERCK
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 T...
07.29.2019 MERCK
Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fuma...
07.24.2019 MERCK
1 2 3 4 5 6 7 8 9 10